Insulet CorpBillerica, United Stateswww.insulet.com/
|Asset Classes||Listed equity|
|Impact strategy||Impact Equities and Bonds|
|Bloomberg ticker||PODD US|
|Industry group||Health Care Equipment & Services|
|Aligned with SDGs|
Insulet is primarily engaged in the development, manufacturing and sale of its OmniPod Insulin Management System. The OmniPod System is an insulin infusion system for people with insulin-dependent diabetes, which includes both Type 1 and Type 2 diabetes patients. The system is designed to provide people with insulin-dependent diabetes with a diabetes management solution which provides mobility and discreetness, and it expands the use of continuous subcutaneous insulin infusion (CSII) therapy.
Insulet is also involved in the distribution of durable medical equipment, including blood glucose testing supplies, insulin pumps, pump supplies, pharmaceuticals, and other products for the management and treatment of diabetes. The OmniPod System is currently available for distribution in the US, Canada and in certain countries in Europe and the Middle East. Insulet was founded in 2000.
In 2021, approximately 537 million adults (20-79 years) are living with diabetes. This number is projected to increase to 643 million by 2030 and 783 million by 2045, meaning it's a growing problem.
Insulet contributes directly to our Healthy & Prosperous People theme by means of its development, production and distribution of the OmniPod system. Maintaining near-normal blood glucose levels helps people with insulin-dependent diabetes live a longer, healthier life with fewer diabetes-related complications. Continuous insulin delivery at preset rates eliminates the need for injections and the interruptions that come with them. In addition, with the OmniPod System, insulin delivery can be changed with the press of a button to adapt to snacks or unexpected changes in daily routine. The OmniPod System's practical benefits include convenience, freedom, flexibility and ease of use.